Oral Transmucosal Drugs Market Size

Oral Transmucosal Drugs Market was valued at around USD 34.3 billion in 2023 and is expected to register a CAGR of 6.7% during the forecast period. The market is expected to experience growth driven by the increasing prevalence of chronic diseases coupled with the rising demand for oral transmucosal drugs.

The increasing prevalence of chronic diseases presents a significant concern, as an increasing number of individuals grapple with persistent health conditions that are typically incurable. Factors such as genetic predisposition, sedentary lifestyles, and an aging population, among others, are contributing to this trend. According to the Centers for Disease Control and Prevention (CDC), chronic diseases like heart disease, cancer, and diabetes are the primary causes of death and disability in the U.S., accounting for a substantial portion of the nation's annual healthcare expenditure, estimated at USD 4.1 trillion. In 2021, coronary heart disease (CHD) alone claimed 375,476 lives in the U.S., establishing it as the most prevalent form of heart disease. Consequently, the rising prevalence of chronic diseases is expected to drive growth in the oral transmucosal drugs market.

Oral transmucosal drugs are medications designed to be administered through the mucous membranes lining the mouth. This route of administration allows for rapid absorption of the drug into the bloodstream, bypassing the gastrointestinal tract and avoiding first-pass metabolism in the liver.